About Us

The GlycoMark test is an FDA-cleared, non-fasting serum or plasma test for monitoring blood glucose variability in people with diabetes.  The GlycoMark test provides quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The test is for professional use, and is indicated for the intermediate term monitoring of glycemic control in people with diabetes.

The GlycoMark 1,5-anhydroglucitol biomarker was discovered to be linked to diabetes by a Japanese researcher in the 1980s. Subsequently, over 40 clinical trials of the marker have been completed around the world. The test has been used in Japan as a standard glycemic biomarker since the early 1990s.

GlycoMark, Inc. is a joint venture of Toyota Tsusho America, Inc. (New York, NY), Toyota Tsusho Corporation (Tokyo, Japan), and Nippon Kayaku Co., Ltd. (Tokyo, Japan).  GlycoMark, Inc. brings exceptional resources to the discovery and commercialization of innovative biomarkers for diabetes.

Nippon Kayaku, Co., Ltd., a major Japanese pharmaceutical and biochemical firm, makes the GlycoMark test. Toyota Tsusho Corporation imports the GlycoMark test from Japan and provides commercialization support through GlycoMark, Inc.

GlycoMark Team


Hirotaka ``Hiro`` Ishibashi

President, GlycoMark, Inc.

Hiro has more than 10 years’ experience in the biotech industry, specifically with GlycoMark. He has worked in research and analysis, and is a senior manager with Toyota Tsusho America.

Hiro is in charge of GlycoMark’s international business development efforts in the Asian Pacific region, India, the Middle East and Latin America. He participates in international conferences on diabetes and on diagnostics/biomarkers. Hiro holds a Master’s degree in Biotechnology from Columbia University.

Jeff Dahlen

Jeff Dahlen, Ph.D.

Vice President of Clinical and Scientific Affairs

Jeff Dahlen, Ph.D., has worked in the in-vitro diagnostics industry for more than 15 years. Prior to joining GlycoMark, he held leadership positions in assay development, clinical affairs, regulatory affairs, medical affairs, and scientific affairs at Biosite, Oculir, and Accumetrics.

Jeff holds a Bachelor of Science degree in Engineering from the University of Illinois and a Ph.D. in Biomedical Sciences (Biochemistry and Molecular Biology) from the University of New Mexico.

Kelly McHugh

Business Development Executive, Diabetes Group

Kelly McHugh is the executive responsible for GlycoMark, Inc.’s strategic account development in the northern U.S. market. Kelly has 20 years of experience in channel distribution and laboratory partnerships in the molecular diagnostics and clinical laboratory industries.

Before coming to GlycoMark in 2015, Kelly was part of the start-up team at Ariosa Dx. She led Ariosa Dx’s business development activities in the eastern U.S.


Carl Abbatecola

Business Development Executive, Diabetes Group

Carl Abbatecola has over 10 years’ experience in the laboratory industry. He started his career with a Miami-based anatomical pathology laboratory specializing in early cancer detection. Carl expanded his laboratory experience as leader of Women’s Health Initiatives for Clinical Pathology Laboratory Southeast.

Carl joined GlycoMark, Inc. in 2012. He manages the company’s sales efforts in the southern United States.

Jeff Johnston

Jeff Johnston

Marketing Executive

Jeff joined the Glycomark team in January, 2015 after 25 years in brand communications in New York City. His brand experience includes work with Siemens, Sylvania, British Telecom and Humana. He has been active in media as a publisher of lifestyle consumer magazines.

In 2007, Jeff managed media relations for the World Forum on Democracy. He has won numerous international awards for creative communications and is a member of the National Press Club in Washington.